RAPID

• Research type

  Research Study

• Full title

  Registry of Asthma Patients Initiating DUPIXENT® (RAPID)

• IRAS ID

  314225

• Contact name

  Andrew Menzies-Gow

• Contact email

  a.menzies-gow@rbht.nhs.uk

• Sponsor organisation

  Regeneron Pharmaceuticals, Inc

• Clinicaltrials.gov Identifier

  EUPAS41963, EU PAS Register Number

• Duration of Study in the UK

  3 years, 10 months, 0 days

• Research summary

  The primary objective of the study is to characterize the patients who initiate treatment for asthma with DUPIXENT® in a real-world setting to understand the attributes of treated patients in real life.
  This includes characterization of:
  • Patient demographics (eg, gender, age, and race)
  • Patient baseline characteristics (eg, prior medications and procedures, medical history, asthma history, weight, height)

  The secondary objectives of the study are:
  • To characterize real-world use patterns of DUPIXENT® for asthma
  • To assess the long-term effectiveness of DUPIXENT® in asthma patients in a real-world
  setting
  • To assess effectiveness on comorbid type 2 inflammatory conditions in asthma
  patients treated with DUPIXENT®
  • To collect long-term safety data on study participants in the real-world setting

• REC name

  South Central - Oxford A Research Ethics Committee

• REC reference

  22/SC/0173

• Date of REC Opinion

  16 Aug 2022

• REC opinion

  Further Information Favourable Opinion